Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) represents the majority of liver cancer and is the fourth most common cause of cancer‐related death. Although advances in molecular targeted therapy have shown promise, none of these agents has yet demonstrated significant clinical benefit. Bromo‐ and extraterminal dom...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chen, Miao, Xiaolong, Wang, Yao, Wen, Liang, Cheng, Xiawei, Kong, Deqiang, Zhao, Pengwei, Song, Dandan, Wang, Xinyi, Ding, Xianfeng, Xia, Hongguang, Wang, Weilin, Sun, Qiming, Gong, Weihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Basic and Clinical Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540980/
https://www.ncbi.nlm.nih.gov/pubmed/32726482
http://dx.doi.org/10.1111/cas.14588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540980/
https://www.ncbi.nlm.nih.gov/pubmed/32726482
http://dx.doi.org/10.1111/cas.14588

Ejemplares similares